171 related articles for article (PubMed ID: 15550036)
1. Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Cimminiello C; Planès A; Samama MM
J Thromb Haemost; 2004 Nov; 2(11):2036-40. PubMed ID: 15550036
[No Abstract] [Full Text] [Related]
2. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
3. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
[No Abstract] [Full Text] [Related]
4. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Tangelder MJ; Bylock A; Held P
Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
[No Abstract] [Full Text] [Related]
5. Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents.
Iorio A
J Thromb Haemost; 2004 Jul; 2(7):1055-7. PubMed ID: 15219186
[No Abstract] [Full Text] [Related]
6. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
7. The METHRO trials.
Hamaad A; Tayebjee MH; Lip GY
Expert Opin Investig Drugs; 2003 May; 12(5):865-70. PubMed ID: 12720496
[TBL] [Abstract][Full Text] [Related]
8. [New antithrombotic agents. Towards a new therapeutic plan].
Fiessinger JN
Rev Prat; 2003 May; 53(10):1063-4. PubMed ID: 12846024
[No Abstract] [Full Text] [Related]
9. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
[TBL] [Abstract][Full Text] [Related]
10. Prevention of venous thromboembolism after major orthopedic surgery: 'new' clinical trials for new antithrombotic agents.
Mismetti P
J Thromb Haemost; 2003 Dec; 1(12):2474-6. PubMed ID: 14675081
[No Abstract] [Full Text] [Related]
11. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Wille-Jorgensen P
Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
[No Abstract] [Full Text] [Related]
12. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
Turpie AG
Int J Clin Pract; 2004 May; 58(5):483-93. PubMed ID: 15206506
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of deep vein thrombosis with ximelagatran].
Caspary L; Bauersachs R; Brehme S; Creutzig A; Harenberg J; Hoffmann U; Landgraf H; Schellong S
Dtsch Med Wochenschr; 2004 Jul; 129(30):1635-40. PubMed ID: 15257504
[No Abstract] [Full Text] [Related]
14. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
Rosencher N
Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
[TBL] [Abstract][Full Text] [Related]
16. More on: Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Eriksson BI
J Thromb Haemost; 2005 Mar; 3(3):611-2. PubMed ID: 15748270
[No Abstract] [Full Text] [Related]
17. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Eriksson BI
Thromb Res; 2003 Jul; 109 Suppl 1():S23-9. PubMed ID: 12818631
[TBL] [Abstract][Full Text] [Related]
18. [The first oral thrombin inhibitor. Competition to heparins and marcumar?].
MMW Fortschr Med; 2003 Mar; 145(10):56. PubMed ID: 12688030
[No Abstract] [Full Text] [Related]
19. Ximelagatran for prevention and treatment of venous thromboembolism.
Kwok L; Boucher M
Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
[TBL] [Abstract][Full Text] [Related]
20. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
